Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases. ...Middle East

PR Newswire - Economy
Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases.
COPENHAGEN, Denmark, Aug. 30, 2023 /PRNewswire/ -- Embark Laboratories announced today that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a three-year research and development collaboration to discover and develop novel pharmaceuticals to...

Hence then, the article about novo nordisk acquires embark biotech including its lead asset targeting obesity and other cardiometabolic diseases was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases. )

Apple Storegoogle play

Last updated :

Also on site :



Latest News